Plus Therapeutics (NASDAQ:CNSY) Stock Rating Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Plus Therapeutics (NASDAQ:CNSY) from a hold rating to a strong sell rating in a research report report published on Wednesday,Zacks reports.

Separately, Weiss Ratings initiated coverage on Plus Therapeutics in a research note on Tuesday, August 4th. They issued a “sell (e+)” rating for the company. Two investment analysts have rated the stock with a Sell rating. According to data from MarketBeat.com, Plus Therapeutics currently has a consensus rating of “Sell”.

Plus Therapeutics Trading Up 11.2%

Shares of CNSY opened at $1.88 on Wednesday. The stock’s 50-day moving average price is $2.50. Plus Therapeutics has a one year low of $1.49 and a one year high of $18.89. The firm has a market cap of $14.27 million, a PE ratio of -0.56 and a beta of 1.47.

Plus Therapeutics (NASDAQ:CNSY) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.35). The firm had revenue of $0.41 million for the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. As a group, equities research analysts predict that Plus Therapeutics will post -4.40 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s lead investigational product is RNL, also known as rhenium-186 nanoliposome, an experimental treatment designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Plus Therapeutics is primarily evaluating RNL in cancers of the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.